4Suppliers
8Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Insight Molecular Diagnostics Inc. (IMDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships
5Distinct source URLs
9High confidence
0.806Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Insight Molecular Diagnostics Inc. Suppliers

TickerNameConfidenceEvidence
BIO-RAD BIO-RAD 92% The Company has a concentration in the volume of business transacted with Bio-Rad, its global strategic partner.
BIO Bio-Rad Laboratories, Inc. 72% Reciprocal relationship from BIO graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from BIO graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from BIO grap…
LCTX Lineage Cell Therapeutics, Inc. 72% ission or proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, or reduce our ability t…
LCTX Lineage Cell Therapeutics, Inc. 72% Reciprocal relationship from LCTX graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from IMDX graph: ission or proceeding could reduce t…

Insight Molecular Diagnostics Inc. Customers

TickerNameConfidenceEvidence
DGX Quest Diagnostics Incorporated 92% Reciprocal relationship from DGX graph: Reciprocal relationship from IMDX graph: On February 20, 2026, iMDx announced that it had entered into a Specimen Collection Agreement with Quest Diagnostics f…
DGX Quest Diagnostics Incorporated 92% On February 20, 2026, iMDx announced that it had entered into a Specimen Collection Agreement with Quest Diagnostics for certain specimen collection-related services related to the Company’s GraftAss…
CAREDX-INC-NATERA-INC CAREDX-INC-NATERA-INC 85% izations that conduct research in our field. Our competition will be determined in part by the potential indications for which our lead test candidates are developed and ultimately marketed. Addition…
CAREDX-INC-NATERA-INC-TRANSPLANT-GENOMICS-OMIXON CAREDX-INC-NATERA-INC-TRANSPLANT-GENOMICS-OMIXON 85% izations that conduct research in our field. Our competition will be determined in part by the potential indications for which our lead test candidates are developed and ultimately marketed. Addition…
BIO Bio-Rad Laboratories, Inc. 72% Reciprocal relationship from BIO graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from BIO graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from BIO grap…
BIO Bio-Rad Laboratories, Inc. 72% s to raise capital to finance its operations. Item 1. Business. Overview We are a pioneering diagnostics technology company. Our mission is to democratize access to novel molecular diagnostic testing…
CALIFORNIA-NORIDIAN-HEALTHCARE-SOLUTIONS-LLC CALIFORNIA-NORIDIAN-HEALTHCARE-SOLUTIONS-LLC 62% to commercialize our products is dependent on availability and sufficiency of third-party payer coverage and our ability to ensure our tests remain reimbursed or attain reimbursement by Medicare, and…
CUSHING-VENTURES-LLC CUSHING-VENTURES-LLC 62% Company recorded impairments of $ 2.9 million and $ 11.7 million related to DetermaIO and DetermaCNI, respectively, as of December 31, 2025 . The significant unobservable inputs used related to Deter…

Insight Molecular Diagnostics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IMDX-DEBT Debt stack $1.9M 90% Market cache reports total debt of $1.9M.
IMDX-DEBT-10234 Warrants outstanding: 819767 90% xbrl warrant detail from xbrl 2023-09-30.
IMDX-DEBT-10235 Xbrl Convertible 90% xbrl convertible detail from xbrl 2017-12-31.

Insight Molecular Diagnostics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc. Ownership

HolderNameConfidenceEvidence
IMDX-OWNER-BROADWOOD-CAPITAL-INC BROADWOOD CAPITAL INC 90% 13F overlay lists BROADWOOD CAPITAL INC as top holder; 43 tracked holders.

Insight Molecular Diagnostics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
IDXG Interpace Biosciences, Inc. 100.00 2
DGX Quest Diagnostics Incorporated 100.00 1 ['customer']
BIO Bio-Rad Laboratories, Inc. 100.00 1 ['customer', 'supplier']
HBIO Harvard Bioscience, Inc. 100.00 2
LCTX Lineage Cell Therapeutics, Inc. 100.00 1 ['supplier']
MXCT MaxCyte, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
APLS Apellis Pharmaceuticals, Inc. 50.00 2
ASTI Ascent Solar Technologies, Inc 50.00 2
PRPH ProPhase Labs, Inc. 50.00 2
QGEN Qiagen N.V. 50.00 2
AWHL Aspira Women's Health Inc. 50.00 2
RENXF Renalytix plc 50.00 2
KPHMW KIORA PHARMACEUTICALS INC 50.00 2
WDI Western Asset Diversified Income Fund 50.00 2
RNLXY Renalytix Plc 50.00 2
GERN Geron Corporation 50.00 2
DYN Dyne Therapeutics, Inc. 50.00 2
NVO Novo Nordisk A/S 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
🔐
IMDX
Unlock IMDX Supply Chain Data
Verified relationships include:
BIO-RADBIO-RADSupplier92%
BIOBio-Rad Laboratories, Inc.Supplier72%
DGXQuest Diagnostics IncorporatedCustomer92%
DGXQuest Diagnostics IncorporatedCustomer92%
+12 more relationships locked
Subscribe, View plans →